After dipping 4.54% yesterday, the shares of Airxpanders (ASX: AXP) traded in massive volumes on the news of treatment success demonstrated in the study conducted on the latest version of AeroForm.
Today, on 4 October 2018, medical device company AirXpanders, Inc. confirmed the treatment success of latest version of AeroForm Tissue Expander system with as high as 96% satisfaction among patients and physicians. The results of V3.0 version of Aeroform device were drawn based on evaluations made in the XPAND Australia post-market clinical study.
As per the study results, primary treatment success was 100% and the treatment success with all cause analysis rate was 98%, inclusive of failure. Whereas, the median days to complete expansion was 21 days, and median time to exchange was 96 days.
The Principal Investigator to the XPAND Australia trial, Dr. Tony Connell stated these latest study results designed to evaluate the improvements in latest version of AeroForm Tissue Expander, have shown enhancement over the previous version of the device while facilitating the treatment success.
AirXpanders told that the outcome of the study confirmed successful completion of second stage breast reconstruction following mastectomy. The revelations have shown considerable reduction in CO2 permeation during clinical use.
The study results were declared at the annual meeting of American Society of Plastic Surgery (ASPS) which was held from 28 September to 1 October 2018. Chief & Medical Director of Plastic Surgery, Dr. Devinder Singh stated “This study clearly confirms that the latest version of AeroForm performs even better than the prior version, and overall satisfaction continues to be very high.” He added “AeroForm continues to be a game-changing alternative for my (Dr. Singh) breast reconstruction patients and a great addition to my (Dr. Singh) practice.
These results were in line with prior clinical results, which showed the AeroForm device scored very high on patient and physician satisfaction and enabled a much earlier time to full expansion than seen in the literature for saline expanders.
President & CEO of AirXpanders, Frank Grillo stated "We very much appreciate the strong commitment to our technology shown by Dr. Connell and the clinical investigators in this study, and we are excited to provide the latest version of our breakthrough AeroForm technology to surgeons and their patients throughout Australia and the US.”
The stock of AirXpanders traded at $0.105 on 4 October 2018. The performance of the stock has fallen by 83.60% over the past one year while it has been seen picking up since the last few months as share price grew by 31.51% over the past three-month period.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.